Black Hawk Acquisition Corp Secures $300K Convertible Note from Sponsor at Deep Discount for DeSPAC
BKHA sits 18% above its 52-week low of $10.09.
Summary
Black Hawk Acquisition Corp secured a convertible promissory note for up to $300,000 from its sponsor to fund working capital for its pending DeSPAC transaction, with a conversion price of $1.00 per share.
Key Events · Financing and Capital Events · BKHA
-
Secures Convertible Note
Black Hawk Acquisition Corp issued a convertible promissory note for up to $300,000 to its sponsor, Black Hawk Management LLC, on May 4, 2026.
-
Working Capital for DeSPAC
The funds are designated for working capital expenses related to the company's ongoing DeSPAC transaction with Vesicor Therapeutics, Inc.
-
Highly Dilutive Conversion Terms
The note bears 10% interest and is convertible into shares of the post-merger company at a price of $1.00 per share, a significant discount to the current market price of $11.86.
-
Sponsor Commitment
The financing from the sponsor indicates their continued commitment to the completion of the business combination, providing crucial capital for the process.
Analysis · BKHA · Life Sciences
This 8-K filing details a critical financing step for Black Hawk Acquisition Corp as it progresses towards its merger with Vesicor Therapeutics, a transaction previously highlighted in an S-4/A filing on May 1, 2026. While the $300,000 convertible note from the sponsor provides necessary working capital to complete the DeSPAC, the conversion terms are highly dilutive for existing shareholders. The sponsor has the option to convert the principal into shares of the post-merger company at a price of $1.00 per share, a substantial discount to the current market price of $11.86. This arrangement highlights the company's need for capital to finalize the merger, but at a significant potential cost in terms of future share dilution. Investors should monitor the closing of the DeSPAC and any subsequent conversion by the sponsor.
How filings like this one have moved
In the 30 days to Oct 29, 2026, 38.8% of the 970 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.46%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BKHA was trading at $11.86 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $49.3M. The 52-week trading range was $10.09 to $11.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.